Contact Us


Weekly Reports ㄗ97ㄘon International Trends of Cutting 每edge Life Science Development
Add Timeㄩ2013/8/1 9:16:44
1. A Full Moon can Disturb a Good Night's Sleep, scientists believe.
Michelle Roberts
Health editor, BBC News onlineㄛ25 July 2013
A Full Moon can Disturb a Good Night's Sleep
Researchers found evidence of a "lunar influence" in a study of 33 volunteers sleeping in tightly controlled laboratory conditions.
When the Moon was round, the volunteers took longer to nod off and had poorer quality sleep, despite being shut in a darkened room, Current Biology reports.
They also had a dip in levels of a hormone called melatonin that is linked to natural-body clock cycles.
When it is dark, the body makes more melatonin. And it produces less when it is light.
※It's one of these folk things that you would suspect has a germ of truth§Dr Neil Stanley
UK sleep expert
Being exposed to bright lights in the evening or too little light during the day can disrupt the body's normal melatonin cycles.
But the work in Current Biology, by Prof Christian Cajochen and colleagues from Basel University in Switzerland, suggests the Moon's effects may be unrelated to its brightness.
2. Autophagy: shaping the tumor microenvironment and therapeutic response
▽Text abstracts▼Trends in Molecular Medicine, Volume 19, Issue 7, 428-446, 28 May 2013
Autophagy: shaping the tumor microenvironment and therapeutic response
Hannelore Maes, Noem赤 Rubio, Abhishek D. Garg et al
Autophagy, the major lysosomal pathway for recycling intracellular components including whole organelles, is emerging as a key process modulating tumorigenesis, tumor每stroma interactions, and cancer therapy. Research over the past decade has highlighted a context-dependent and dynamic role for autophagy in cancer: it is tumor suppressive in the early stages of cancer development, but fuels the growth of established tumors. Likewise, the stimulation of autophagy in response to therapeutics can contextually favor or weaken chemoresistance and antitumor immunity. From a therapeutic perspective, understanding whether, when, and how autophagy can be harnessed to kill cancer cells remains challenging. In this review, we discuss new connections that reveal the role of autophagy in shaping tumor每stroma interaction during carcinogenesis and in the context of anticancer treatments.
3. Collagen VI in cancer and its biological mechanisms
▽Text abstracts▼Trends in Molecular Medicine, Volume 19, Issue 7, 410-417, 01 May 2013
Collagen VI in cancer and its biological mechanisms
Peiwen Chen, Matilde Cescon, Paolo Bonaldo
Collagen VI is a widely distributed extracellular matrix protein highly expressed in a variety of cancers that favors tumor growth and progression. A growing number of studies indicate that collagen VI directly affects malignant cells by acting on the Akt每GSK-3汕每汕-catenin每TCF/LEF axis, enhancing the production of protumorigenic factors and inducing epithelial每mesenchymal transition. Moreover, it affects the tumor microenvironment by increasing the recruitment of macrophages and endothelial cells, thus promoting tumor inflammation and angiogenesis. Furthermore, collagen VI promotes chemotherapy resistance and can be regarded as a potential biomarker for cancer diagnosis. Collectively, these findings strongly support a role for collagen VI as an important regulator in tumors and provide new targets for cancer therapies.
4.Targeting protein每protein interactions as an anticancer strategy
▽Text abstracts▼Trends in Pharmacological Sciences, Volume 34, Issue 7, 393-400, 29 May 2013 ﹛﹛
Targeting protein每protein interactions as an anticancer strategy
The emergence and convergence of cancer genomics, targeted therapies, and network oncology have significantly expanded the landscape of protein每protein interaction (PPI) networks in cancer for therapeutic discovery. Extensive biological and clinical investigations have led to the identification of protein interaction hubs and nodes that are critical for the acquisition and maintenance of characteristics of cancer essential for cell transformation. Such cancer-enabling PPIs have become promising therapeutic targets. With technological advances in PPI modulator discovery and validation of PPI-targeting agents in clinical settings, targeting of PPI interfaces as an anticancer strategy has become a reality. Future research directed at genomics-based PPI target discovery, PPI interface characterization, PPI-focused chemical library design, and patient-genomic subpopulation-driven clinical studies is expected to accelerate the development of the next generation of PPI-based anticancer agents for personalized precision medicine. Here we briefly review prominent PPIs that mediate cancer-acquired properties, highlight recognized challenges and promising clinical results in targeting PPIs, and outline emerging opportunities.
5. Soy protein films for wound-healing applications: antibiotic release, bacterial inhibition and cellular response
▽Text abstracts▼Journal of Tissue Engineering and Regenerative Medicine, Volume 7, Issue 5, pages 401每412, May 2013
Soy protein films for wound-healing applications: antibiotic release, bacterial inhibition and cellular response
Zachi Peles, Itzhak Binderman, Israela Berdicevsky, et al
Use of naturally derived materials is becoming widespread in the biomedical field. Soy protein has advantages over the various types of natural proteins employed for biomedical applications, due to its low price, non-animal origin and relatively long storage time and stability. In the current study, soy protein isolate (SPI) was investigated as a matrix for wound-dressing applications. The antibiotic drug gentamicin was incorporated into the matrix for local controlled release and thus continuous bactericidal effect. Homogeneous high-quality films were cast from aqueous solutions and tested for the effects of gentamicin release on bacterial inhibition. The cytotoxicity and in vitro biocompatibility of these films were also examined. The gentamicin release profiles exhibited a moderate burst effect followed by a decreasing release rate, which was maintained for at least 4 weeks, thus enabling a suitable bacterial inhibition effect. The materials released from the films during an indirect cytotoxicity test were found to be safe, except for a slight inhibitory effect in the presence of high concentrations of glycerol. The biocompatibility test showed confluent cell cultures in close proximity to the SPI films. It is clear that these new antibiotic-eluting SPI films exhibit a high potential for use as wound dressings. Copyright © 2012 John Wiley & Sons, Ltd.

  • You can post your comments on this article. Please fill in the following box as guided.

    About us | Contact us | Link | Version | Sitemap | Glossary
    Copyright© 2009 mebo.Com .All Rights Reserved